[go: up one dir, main page]

NO20023837D0 - Modulering av bendannelse - Google Patents

Modulering av bendannelse

Info

Publication number
NO20023837D0
NO20023837D0 NO20023837A NO20023837A NO20023837D0 NO 20023837 D0 NO20023837 D0 NO 20023837D0 NO 20023837 A NO20023837 A NO 20023837A NO 20023837 A NO20023837 A NO 20023837A NO 20023837 D0 NO20023837 D0 NO 20023837D0
Authority
NO
Norway
Prior art keywords
modulation
bone formation
bone
formation
Prior art date
Application number
NO20023837A
Other languages
English (en)
Other versions
NO20023837L (no
Inventor
Andrew Scutt
Karen Still
Original Assignee
Univ Sheffield
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Sheffield filed Critical Univ Sheffield
Publication of NO20023837D0 publication Critical patent/NO20023837D0/no
Publication of NO20023837L publication Critical patent/NO20023837L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
NO20023837A 2000-02-15 2002-08-14 Modulering av bendannelse NO20023837L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0003310.0A GB0003310D0 (en) 2000-02-15 2000-02-15 Bone formation
PCT/GB2001/000626 WO2001060355A1 (en) 2000-02-15 2001-02-15 Modulation of bone formation

Publications (2)

Publication Number Publication Date
NO20023837D0 true NO20023837D0 (no) 2002-08-14
NO20023837L NO20023837L (no) 2002-10-14

Family

ID=9885521

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20023837A NO20023837L (no) 2000-02-15 2002-08-14 Modulering av bendannelse

Country Status (18)

Country Link
US (1) US20030139372A1 (no)
EP (1) EP1259233A1 (no)
JP (1) JP2003522787A (no)
KR (1) KR20020093808A (no)
CN (1) CN1430512A (no)
AU (1) AU3212101A (no)
BR (1) BR0108344A (no)
CA (1) CA2399810A1 (no)
CZ (1) CZ20022741A3 (no)
GB (1) GB0003310D0 (no)
HK (1) HK1049618A1 (no)
HU (1) HUP0204511A3 (no)
IL (1) IL151243A0 (no)
MX (1) MXPA02007901A (no)
NO (1) NO20023837L (no)
NZ (1) NZ520764A (no)
WO (1) WO2001060355A1 (no)
ZA (1) ZA200206318B (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716842B2 (en) 2002-04-05 2004-04-06 Warner-Lambert Company, Llc Antidiabetic agents
AU2003257854A1 (en) * 2003-05-28 2005-01-21 Eisai R&D Management Co., Ltd Compositions and foods and drinks contiaing higher fatty acid derivative
WO2005039485A2 (en) * 2003-08-13 2005-05-06 Chiron Corporation Gsk-3 inhibitors and uses thereof
PL1667964T3 (pl) * 2003-09-19 2010-01-29 Janssen Pharmaceutica Nv Kwasy 4-((fenoksyalkilo)tio)-fenoksyoctowe i analogi
JP5016922B2 (ja) * 2003-09-19 2012-09-05 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ４−（（フェノキシアルキル）チオ）−フェノキシ酢酸および類似化合物
WO2006126541A1 (ja) * 2005-05-27 2006-11-30 Shionogi & Co., Ltd. ビタミンｋ類含有医薬組成物
NO20053517L (no) * 2005-07-18 2007-01-19 Thia Medica As Anvendelse av lipidsenkende midler
US20090163481A1 (en) * 2007-12-13 2009-06-25 Murphy Brian J Ppar-delta ligands and methods of their use
KR101417201B1 (ko) * 2008-01-02 2014-07-08 마린 바이오 씨오., 엘티디. 신경변성 질환을 치료하기 위한 조성물 및 방법
WO2010137944A1 (en) 2009-05-27 2010-12-02 N.V. Nutricia Treatment of hypercalcaemia
CA2863183A1 (en) * 2012-02-15 2013-08-22 Basf Se Means and methods for assessing bone disorders
US9763911B2 (en) 2013-12-12 2017-09-19 Mayo Foundation For Medical Education And Research Prostacyclin compositions for regulation of fracture repair and bone formation
CN105327333B (zh) * 2015-10-30 2018-09-07 大连大学 可促进牙种植体周围成骨的口腔施用组合物及其制剂
CN110433156A (zh) * 2019-08-27 2019-11-12 成都元素平衡生物科技有限公司 芝麻素在成骨分化中的新应用
WO2021046081A1 (en) * 2019-09-05 2021-03-11 Rush University Medical Center Methods and compositions for treatment of demyelinating disorders
CN111789833A (zh) * 2020-08-31 2020-10-20 苏州大学 2-溴棕榈酸在制备防治骨丢失相关疾病的药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5312814A (en) * 1992-12-09 1994-05-17 Bristol-Myers Squibb Co. α-phosphonocarboxylate squalene synthetase inhibitors
EP0783888A1 (en) * 1995-12-26 1997-07-16 Sankyo Company Limited Use of troglitazone and related thiazolidinediones in the manufacture of a medicament for the treatment and prophylaxis of osteoporosis
JPH09295936A (ja) * 1996-04-30 1997-11-18 Kowa Techno Saac:Kk 人工透析患者の骨疾患治療用外用剤
US5804210A (en) * 1996-08-07 1998-09-08 Wisconsin Alumni Research Foundation Methods of treating animals to maintain or enhance bone mineral content and compositions for use therein
US5925657A (en) * 1997-06-18 1999-07-20 The General Hospital Corporation Use of PPARγ agonists for inhibition of inflammatory cytokine production
EP1028724A1 (en) * 1997-11-10 2000-08-23 Novo Nordisk A/S Transdermal delivery of 3,4-diarylchromans
GB9824614D0 (en) * 1998-11-11 1999-01-06 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
BR0108344A (pt) 2003-03-11
NZ520764A (en) 2004-05-28
EP1259233A1 (en) 2002-11-27
ZA200206318B (en) 2003-11-07
HUP0204511A3 (en) 2004-11-29
IL151243A0 (en) 2003-04-10
HK1049618A1 (zh) 2003-05-23
AU3212101A (en) 2001-08-27
CN1430512A (zh) 2003-07-16
KR20020093808A (ko) 2002-12-16
HUP0204511A2 (en) 2003-05-28
MXPA02007901A (es) 2004-09-10
WO2001060355A1 (en) 2001-08-23
US20030139372A1 (en) 2003-07-24
NO20023837L (no) 2002-10-14
CZ20022741A3 (cs) 2003-03-12
JP2003522787A (ja) 2003-07-29
GB0003310D0 (en) 2000-04-05
CA2399810A1 (en) 2001-08-23

Similar Documents

Publication Publication Date Title
ATE411332T1 (de) 3'-prodrugs von 2'-deoxy-beta-l-nukleosiden
AR028253A1 (es) Inhibidores de la glucogeno fosforilasa
AR028596A1 (es) Nuevos derivados de fenilglicina
ID27092A (id) Pembuatan ftalat anhidrida
DK1252293T3 (da) Kilde til levervæv
ID30187A (id) Dongkrak jenis pantagraf
NO20024890L (no) Implantat
NO20023837L (no) Modulering av bendannelse
NO20034127L (no) Forbedring av aromainneholdende bestanddeler
DE59808818D1 (de) Chirurgischer Spreizer
AU9658701A (en) Modulation of allergic response
NO20035380D0 (no) Fremgangsmåte for dannelse av m degree nster
NO20041968L (no) Anvendelse av cystationin
DE60107074D1 (de) Kristallin form ii von cabergolin
NO20016151D0 (no) Fremstilling av substituerte piperidin-4-oner
PT1322592E (pt) Derivados substituidos de 1-aminobutan-3-ol
FR2806309B1 (fr) Implant
DE60126734D1 (de) Superiostealer Knochenanker
DE60007360D1 (de) Amorphe modifikation von torasemid
EP1261346A4 (en) REGULATING A CARDIOVASCULAR INJURY
NO20004109L (no) Stabilisering av formasjoner
NO20014845D0 (no) Anvendelse av arylalkanoylpyridaziner
SE0300535L (sv) Behandling av brännskador
EP1333856A4 (en) MODULATION OF ANGIOGENESIS
NO20025765L (no) Kombinasjonssett for behandling av malaria

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application